Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)
China · Delayed Price · Currency is CNY 37.44
-1.16 (-3.01%)
Apr 9, 2026, 3:04 PM CST
SHE:300683 Revenue
Wuhan Hiteck Biological Pharma Co.,Ltd had revenue of 146.84M CNY in the quarter ending September 30, 2025, a decrease of -11.74%. This brings the company's revenue in the last twelve months to 619.88M, up 0.82% year-over-year. In the year 2024, Wuhan Hiteck Biological Pharma Co.,Ltd had annual revenue of 648.97M with 7.75% growth.
Revenue (ttm)
619.88M
Revenue Growth
+0.82%
P/S Ratio
7.91
Revenue / Employee
473.55K
Employees
1,309
Market Cap
4.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 648.97M | 46.69M | 7.75% |
| Dec 31, 2023 | 602.28M | -86.34M | -12.54% |
| Jan 1, 2023 | 688.63M | 73.94M | 12.03% |
| Jan 1, 2022 | 614.68M | 90.56M | 17.28% |
| Dec 31, 2020 | 524.12M | -96.04M | -15.49% |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ZhuZhou QianJin Pharmaceutical Co.,Ltd | 3.63B |
| Jianmin Pharmaceutical Group | 3.37B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Zhuhai Rundu Pharmaceutical | 1.19B |
| Beijing Beilu Pharmaceutical | 1.13B |
| Teyi Pharmaceutical Group Co.,Ltd | 924.53M |
| ChengDu ShengNuo Biotec | 741.34M |
| Nanjing Hicin Pharmaceutical | 615.39M |